Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts. As of June 11, 2024, Deciphera Pharmaceuticals, Inc. operates as a subsidiary of Ono Pharmaceutical Co., Ltd.
Frequently asked questions
What sector does Deciphera Pharmaceuticals Inc (D05) operate in?
Deciphera Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Deciphera Pharmaceuticals Inc (D05) current stock price?
As of the latest data, Deciphera Pharmaceuticals Inc stock price is €53.93, with a previous close of €53.93.
What is Deciphera Pharmaceuticals Inc (D05) current market capitalization?
Deciphera Pharmaceuticals Inc market cap is approximately 4.66 billion.
What is Deciphera Pharmaceuticals Inc (D05) Earnings Per Share (EPS)?
The trailing EPS is -€2.05, and the forward EPS is -€3.78.
Does Deciphera Pharmaceuticals Inc (D05) pay dividends?
No. Deciphera Pharmaceuticals Inc does not pay a dividend.
What is Deciphera Pharmaceuticals Inc (D05) beta (volatility) score?
Deciphera Pharmaceuticals Inc has a beta of 0.184, indicating lower volatility than the overall market.
